Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Pharmacokinetics

Busulfan pharmacokinetics do not predict relapse in acute myeloid leukemia

Bone Marrow Transplantation volume 26, pages 607–614 (2000)Cite this article

Abstract

The purpose of this study was to evaluate the influence of busulfan (BU) pharmacokinetics on survival, grades II–IV acute graft-versus-host disease (GVHD), non-relapse mortality (NRM) and relapse in a group composed of 45 children (<18 years) and seven adults with acute myeloid leukemia (aml) in first complete remission and undergoing hematopoietic stem cell transplantation (sct). fifty-two patients underwent autologous (n = 25) or allogeneic (n = 27) SCT. The median age was 8.9 years (range 0.6–53 years). Conditioning therapy consisted of BU and cyclophosphamide. Improved disease-free survival was found in those patients with a steady-state concentration of BU (CssBU) below the median (<578 mg/ml, P = 0.05), and the same trend was noted for overall survival (P = 0.07). This was secondary to a higher incidence of NRM in the group of patients with CssBU above the median (P = 0.06). There was no significant correlation with CssBU and relapse (P = 0.31). No association between CssBU and GVHD was found in allogeneic patients (P = 0.30). Relapse was evaluated among the subgroups of age (< or >10 years) and transplant type (allogeneic or autologous) with no statistically significant association observed among these factors. Multiple regression analysis for relapse revealed no significant correlation with CssBU above or below the median, age, or transplant type. In this study, CssBU below the median did not correlate with an inferior outcome for patients with AML. Pharmacokinetic dosing of BU may be important for prevention of NRM but does not appear to influence the risk of relapse in this largely pediatric population with AML. Bone Marrow Transplantation (2000) 26, 607–614.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Blazar BR, Ramsay NK, Kersey JH et al. Pretransplant conditioning with busulfan (Myleran) and cyclophosphamide for nonmalignant diseases. Assessment of engraftment following histocompatible allogeneic bone marrow transplantation Transplantation 1985 39: 597–603

    CAS  PubMed  Google Scholar 

  2. Parkman R, Rappeport JM, Hellman S et al. Busulfan and total body irradiation as antihematopoietic stem cell agents in the preparation of patients with congenital bone marrow disorders for allogenic bone marrow transplantation Blood 1984 64: 852–857

    CAS  PubMed  Google Scholar 

  3. Lucarelli G, Polchi P, Galimberti M et al. Marrow transplantation for thalassaemia following busulphan and cyclophosphamide Lancet 1985 1: 1355–1357

    CAS  PubMed  Google Scholar 

  4. Hassan M, Ehrsson H, Ljungman P . Aspects concerning busulfan pharmacokinetics and bioavailability Leuk Lymphoma 1996 22: 395–407

    CAS  PubMed  Google Scholar 

  5. Vassal G, Gouyette A, Hartmann O et al. Pharmacokinetics of high-dose busulfan in children Cancer Chemother Pharmacol 1989 24: 386–390

    CAS  PubMed  Google Scholar 

  6. Hassan M, Oberg G, Bekassy AN et al. Pharmacokinetics of high-dose busulphan in relation to age and chronopharmacology Cancer Chemother Pharmacol 1991 28: 130–134

    CAS  PubMed  Google Scholar 

  7. Grochow LB, Krivit W, Whitley CB et al. Busulfan disposition in children Blood 1990 75: 1723–1727

    CAS  PubMed  Google Scholar 

  8. Vassal G, Fischer A, Challine D et al. Busulfan disposition below the age of three: alteration in children with lysosomal storage disease Blood 1993 82: 1030–1034

    CAS  PubMed  Google Scholar 

  9. Vassal G, Challine D, Koscielny S et al. Chronopharmacology of high-dose busulfan in children Cancer Res 1993 53: 1534–1537

    CAS  PubMed  Google Scholar 

  10. Buggia I, Zecca M, Alessandrino EP et al. Itraconazole can increase systemic exposure to busulfan in patients given bone marrow transplantation. GITMO (Gruppo Italiano Trapianto di Midollo Osseo) Anticancer Res 1996 16: 2083–2088

    CAS  PubMed  Google Scholar 

  11. Hassan M, Fasth A, Gerritsen B et al. Busulphan kinetics and limited sampling model in children with leukemia and inherited disorders Bone Marrow Transplant 1996 18: 843–850

    CAS  PubMed  Google Scholar 

  12. Buggia I, Locatelli F, Regazzi MB et al. Busulfan Ann Pharmacother 1994 28: 1055–1062

    CAS  PubMed  Google Scholar 

  13. Hassan M, Oberg G, Bjorkholm M et al. Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics Cancer Chemother Pharmacol 1993 33: 181–186

    CAS  PubMed  Google Scholar 

  14. Regazzi MB, Locatelli F, Buggia I et al. Disposition of high-dose busulfan in pediatric patients undergoing bone marrow transplantation Clin Pharmacol Ther 1993 54: 45–52

    CAS  PubMed  Google Scholar 

  15. Hassan M, Ljungman P, Bolme P et al. Busulfan bioavailability Blood 1994 84: 2144–2150

    CAS  PubMed  Google Scholar 

  16. Vassal G, Deroussent A, Challine D et al. Is 600 mg/m2 the appropriate dosage of busulfan in children undergoing bone marrow transplantation? Blood 1992 79: 2475–2479

    CAS  PubMed  Google Scholar 

  17. Yeager AM, Wagner JE Jr, Graham ML et al. Optimization of busulfan dosage in children undergoing bone marrow transplantation: a pharmacokinetic study of dose escalation Blood 1992 80: 2425–2428

    CAS  PubMed  Google Scholar 

  18. Poonkuzhali B, Srivastava A, Quernin MH et al. Pharmacokinetics of oral busulphan in children with beta thalassaemia major undergoing allogeneic bone marrow transplantation Bone Marrow Transplant 1999 24: 5–11

    CAS  PubMed  Google Scholar 

  19. Santos GW, Tutschka PJ, Brookmeyer R et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide New Engl J Med 1983 309: 1347–1353

    CAS  PubMed  Google Scholar 

  20. Tutschka PJ, Santos GW . Bone marrow transplantation in the busulfin-treated rat. III. Relationship between myelosuppression and immunosuppression for conditioning bone marrow recipients Transplantation 1977 24: 52–62

    CAS  PubMed  Google Scholar 

  21. Chattergoon DS, Saunders EF, Klein J et al. An improved limited sampling method for individualised busulphan dosing in bone marrow transplantation in children Bone Marrow Transplant 1997 20: 347–354

    CAS  PubMed  Google Scholar 

  22. Demirer T, Buckner CD, Appelbaum FR et al. Busulfan, cyclophosphamide and fractionated total body irradiation for allogeneic marrow transplantation in advanced acute and chronic myelogenous leukemia: phase I dose escalation of busulfan based on targeted plasma levels Bone Marrow Transplant 1996 17: 341–346

    CAS  PubMed  Google Scholar 

  23. Slattery JT, Sanders JE, Buckner CD et al. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics (published erratum appears in Bone Marrow Transplant 1996; 18:829) Bone Marrow Transplant 1995 16: 31–42

    CAS  PubMed  Google Scholar 

  24. Slattery JT, Clift RA, Buckner CD et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation Blood 1997 89: 3055–3060

    CAS  PubMed  Google Scholar 

  25. Dix SP, Wingard JR, Mullins RE et al. Association of busulfan area under the curve with veno-occlusive disease following BMT Bone Marrow Transplant 1996 17: 225–230

    CAS  PubMed  Google Scholar 

  26. Grochow LB, Jones RJ, Brundrett RB et al. Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation Cancer Chemother Pharmacol 1989 25: 55–61

    CAS  PubMed  Google Scholar 

  27. Ljungman P, Hassan M, Bekassy AN et al. High busulfan concentrations are associated with increased transplant-related mortality in allogeneic bone marrow transplant patients Bone Marrow Transplant 1997 20: 909–913

    CAS  PubMed  Google Scholar 

  28. Vassal G, Deroussent A, Hartmann O et al. Dose-dependent neurotoxicity of high-dose busulfan in children: a clinical and pharmacological study Cancer Res 1990 50: 6203–6207

    CAS  PubMed  Google Scholar 

  29. Deeg HJ, Storb R . Graft-versus-host disease: pathophysiological and clinical aspects Annu Rev Med 1984 35: 11–24

    CAS  PubMed  Google Scholar 

  30. Weisdorf DJ, Snover DC, Haake R et al. Acute upper gastrointestinal graft-versus-host disease: clinical significance and response to immunosuppressive therapy Blood 1990 76: 624–629

    CAS  PubMed  Google Scholar 

  31. Pawlowska AB, Blazar BR, Angelucci E et al. Relationship of plasma pharmacokinetics of high-dose oral busulfan to the outcome of allogeneic bone marrow transplantation in children with thalassemia Bone Marrow Transplant 1997 20: 915–920

    CAS  PubMed  Google Scholar 

  32. Kaplan EL, Meier P . Nonparametric estimation from incomplete observations J Am Stat Assoc 1958 53: 457–481

    Google Scholar 

  33. Cox DR . Regression models and life-tables J R Stat Soc 1972 34: 187–202

    Google Scholar 

  34. Davies SM, Ramsay NK, Klein JP et al. Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia J Clin Oncol 2000 18: 340–347

    CAS  PubMed  Google Scholar 

  35. Shankar SM, Bunin NJ, Moshang T Jr . Growth in children undergoing bone marrow transplantation after busulfan and cyclophosphamide conditioning J Pediatr Hematol Oncol 1996 18: 362–366

    CAS  PubMed  Google Scholar 

  36. Michel G, Socie G, Gebhard F et al. Late effects of allogeneic bone marrow transplantation for children with acute myeloblastic leukemia in first complete remission: the impact of conditioning regimen without total-body irradiation – a report from the Société Française de Greffe de Moelle J Clin Oncol 1997 15: 2238–2246

    CAS  PubMed  Google Scholar 

  37. Adan L, de Lanversin ML, Thalassinos C et al. Growth after bone marrow transplantation in young children conditioned with chemotherapy alone Bone Marrow Transplant 1997 19: 253–256

    CAS  PubMed  Google Scholar 

  38. Vaughan WP, Cagnoni P, Fernandez H et al. Decreased incidence of and risk factor for hepatic veno-occlusive disease with an intravenous busulfan (BU) containing preparative regimen for hematopoietic stem cell transplantation (HSCT) Blood 1998 92: 516a

    Google Scholar 

  39. Andersson BS, Cagnoni P, Jones R et al. Allogeneic hemopoietic stem cell transplantation (BMT) after IV busulfan, and cyclophosphamide (BuCy) for acute myeloid leukemia (AML) and myelodysplasia (MDS) Blood 1999 94: 167a

    Google Scholar 

  40. Kashyap A, Wingard J, Cagnoni P et al. Intravenous (IV) vs. oral busulfan (BU) as part of a BU/CY (cyclophosphamide) preparative regimen for allogeneic hematopoietic stem cell transplantation (HSCT): decreased incidence of hepatic veno-occlusive disease (VOD) Blood 1999 94: 321b

    Google Scholar 

Download references

Acknowledgements

This work was supported in part by the Children's Cancer Research Fund, Minneapolis, MN.

Author information

Authors and Affiliations

  1. Division of Hematology/Oncology and Stem Cell Transplantation, University of Minnesota Cancer Center and Department of Pediatrics, Minneapolis, MN, USA

    KS Baker, T DeFor, NKC Ramsay & BR Blazar

  2. Children's Hospital, Minneapolis, MN, USA

    B Bostrom

  3. South Carolina Cancer Center, Columbia, SC, USA

    WG Woods

Authors
  1. KS Baker
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B Bostrom
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T DeFor
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. NKC Ramsay
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. WG Woods
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. BR Blazar
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Baker, K., Bostrom, B., DeFor, T. et al. Busulfan pharmacokinetics do not predict relapse in acute myeloid leukemia. Bone Marrow Transplant 26, 607–614 (2000). https://doi.org/10.1038/sj.bmt.1702590

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1702590

Keywords

This article is cited by

Search

Advanced search

Quick links